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Expanded criteria donor (ECD) kidneys are transplantable
deceased donor (DD) kidneys for which the average patient,
graft survival, and renal function are inferior when compared to
standard criteria DD kidneys. Although the term ECD kidneys
has been used since the early 1990s to describe kidneys with
various characteristics associated with poorer outcomes, the
concept has been formally implemented in U.S. organ allocation.
A DD kidney is considered to be an ECD organ if the estimated








 1.70) compared to
DD kidneys with standard characteristics of transplant suitability.





60 years, or age 50–59 years plus two of the following:
cerebrovascular accident as the cause of death, preexisting
hypertension, or terminal serum creatinine greater than 1.5 mg/
dl. In the aggregate, recipients of ECD kidneys have improved
survival compared to end-stage renal disease (ESRD) patients
on the kidney transplant waiting list. Patient survival is 5%
lower at 1 year and 8–12% lower at 3–5 years for ECD kidney
recipients. Adjusted graft survival in ECD kidneys is 8% lower
at 1 year and 15–20% lower at 3–5 years after transplantation
compared to standard criteria donor kidneys. However, patients
less than 40 years of age, African Americans, Asians for whom
the median waiting time is less than 1350 days receive no survival
benefit from ECD kidney transplantation. Informed choice by
the potential recipient is a prominent feature of the allocation
policy regarding ECD kidneys. Since there are recipient char-
acteristics associated with no survival benefit following ECD
transplantation, nephrologists who refer patients for kidney
transplantation should be familiar with the combination of donor
and recipient factors that are likely to yield detrimental results.
 
Among others, the characteristics of a deceased organ
donor and the physiologic function of the retrieved organ
have a powerful influence on the clinical outcomes of the
organ transplantation. Although the criteria used to define
a transplantable organ are neither uniform nor consistent,
donor-related factors known to be associated with dimin-
ished graft and patient outcomes of deceased donor (DD)
kidney transplantation are well defined. The presence
of greater than 20% globally sclerosed glomeruli on the
preimplantation biopsy; a history of donor hypertension,
diabetes mellitus, hepatitis B or C, malignant neoplasm,
or sepsis in the donor; anatomic abnormalities; extreme
donor age; and gross mismatch in donor-recipient weight
have been implicated as determinants of inferior outcomes
and donor kidneys with these characteristics were often
discarded (1–7). By the early 1990s, consequent to the ever
worsening shortage of donor kidneys and the relentless
expansion of the waiting list, DD kidneys with one or
more of the characteristics that used to be the basis for
discarding retrieved DD kidneys were being transplanted
into patients (6,8–12).
The term “expanded criteria donor” (ECD) was intro-
duced by Kaufman et al. (13) in 1997 to describe trans-
plantable organs that do not meet the criteria for standard
donor organs, in preference to the other descriptive
terminologies that were in use, such as suboptimal,
inferior, or nonstandard donor kidneys. The comparisons
of posttransplant outcomes between standard donor
criteria and ECD kidneys showed, with little exception,
increased risks of primary nonfunction and delayed graft
function, and lower graft survival in the ECD kidneys
(14–19). Patient survival was similar in the short term,
but lower after 5 years or more in the ECD kidneys
(18,20–22). The global picture that emerged from the
published results of ECD kidney transplantation was that
DD kidneys that would have been discarded if there was
an abundance of organs were yielding posttransplant results
that clearly confer significant, albeit inferior, survival
benefits to the recipients, particularly when juxtaposed
against the misery, tedium, and short life expectancy
associated with maintenance dialysis treatment.
By 1997, 10–15% of DD kidneys transplanted in the
United States were ECD kidneys (17,23–25). In an effort
to decrease the discarding of ECD kidneys, the Kidney
Working Group (“Maximizing the Use of Organs
Recovered from the Cadaver Donor,” March 28–29, 2001,
Crystal City, VA) recommended the development of
formal criteria to define the transplanted kidneys that did
not meet the standard criteria and called for research to
define the interaction between recipient characteristics
and nonstandard kidneys with respect to outcomes. Work
from the Scientific Registry of Transplant Recipients
(SRTR) and published data from single-center studies
 




were considered by the Organ Procurement and Trans-
plantation Network (OPTN), which then recommended
the codification of ECD kidneys and proposed a revision
of the allocation policy to optimize the placement of
ECD kidneys (25). In November 2001, the OPTN board
approved the definition of ECD (Table 1) and revised the
allocation policy to require that, at the time of listing,
patients should be given the option of whether or not
they wish to considered for an ECD kidney transplant
(26).
The allocation policy that became operational in
October 2002 (UNOS Policy 3.5, Allocation of Cadaveric
Kidneys) states inter alia “Kidneys procured from the ECD
will be allocated to patients determined to be suitable
candidates: first, for zero antigen mismatched patients
among this group of patients with time limitations; and
next, for all other eligible patients locally, regionally, and
nationally, based on time waiting and not the HLA
matching. The UNOS Organ Center will attempt to place
expanded criteria donor organs for the zero antigen
mismatched patients, according to the national list of
patients waiting for expanded criteria kidneys for a period
of two hours, after which time the UNOS Organ Center
will notify the host OPO that it may allocate the expanded
criteria kidneys by the standard geographic sequence of
local, regional, and national allocation. OPOs are required
to identify potential recipients (i.e., perform a match run
and start the process of notifying the appropriate trans-
plant program(s) regarding the organ offer) for kidneys
they procure from expanded criteria donors within hours
post cross-clamp or offer the organs for eligible patients
listed regionally and the nationally” (26). Since studies
have shown that reluctance to accept ECD kidneys often
leads to excessively long cold ischemia time during the
placement effort, resulting in a high discard rate of these
kidneys (26), the revised allocation policy has two main
thrusts: First, a well-defined time limit was imposed on
the process of offering the ECD kidney to minimize the
cold preservation time, which has been well established
as a risk factor for delayed graft function and possibly
poorer graft survival (27–29); and second, patient
choice was given a prominent role to ensure that trans-
plant candidates are given sufficient information regard-
ing the process of allocation and clinical outcomes of
ECD kidneys. An example of the consent document for
the ECD option on the waiting list is included in the
appendix.
It is important to emphasize that there is no separate
waiting list for ECD kidneys and no points are awarded
for being willing to receive an ECD kidney (i.e., patients
do not advance further on the list based on this choice).
Willingness to receive an ECD kidney is simply a recorded
option that is open to all waiting list registrants, such that
when an ECD kidney becomes available, only those who
have recorded a willingness to receive an ECD kidney
are included in the match run (the computerized nation-
wide algorithm based on specified allocation rules that is
used to allocate all DD organs). Furthermore, a patient
on the waiting list may change their ECD kidney option
at anytime. As of July 2003, 43% of patients on the wait-
ing list for kidney transplantation indicated that they
would consider an ECD kidney offer (30,31). In 20–30%
of donation service areas (geographic units served by an
individual organ procurement organization), 80–100%
of patients on the list were willing to receive an ECD
kidney transplant (30).
 
Characteristics of ECD Kidneys
 
By definition, an ECD kidney results in inferior
clinical outcomes compared to standard criteria donor
kidney. In a broad sense, numerous donor-related attributes
associated with inferior graft results have been used to
define an ECD kidney: risk of infectious disease or
malignancy transmission, donor hypertension or dia-
betes mellitus, donor death due to thrombo-occlusive
cerebrovascular accident, donor mechanism of death
(cardiac death versus brain death), anatomic vascular
abnormalities and histomorphology, donor age greater
than 60 years, donor age less than 10 years, elevated
terminal serum creatinine levels, or a history of high-risk
behavior.
Although implementation of the ECD option in the
OPTN allocation policy is based on a limited number of
simple, easily measurable characteristics (Table 1), any
number of criteria outside the OPTN policy continue to be
used to define ECD kidneys by researchers and clinicians.
When the term ECD kidney is used, it is always useful to
provide the context of whether the definition is based on
the description in the OPTN allocation or whether the term
includes other criteria. For example, it is important to
distinguish an ECD kidney from a kidney that is procured
after cardiac death. Donation after cardiac death (DCD)
is defined as organ donation obtained after the deceased
suffered cardiac arrest, in contrast to the standard
approach in which organ retrieval occurred after primary
brain death while cardiovascular function is maintained.
A DCD kidney may still qualify as an ECD kidney if
the criteria in Table 1 are met. However, in practice,
DCD kidneys are often broadly described as ECD
kidneys.
TABLE 1. Characteristics used to define an expanded criteria 





Donor age categories (years)
< 10 10–39 40–49 50–59 ≥ 60
CVA + HTN + creatinine > 1.5 X X
CVA + HTN X X
CVA + creatinine > 1.5 X X
HTN + creatinine > 1.5 X X
CVA X
HTN X
Creatinine > 1.5 X
None of the above X
The donor must meet the criteria of age ≥ 60 years or age 50–59 
years plus two other criteria to be defined as an expanded criteria 
donor. All other donors who do not fulfill these criteria are described 
as standard criteria donor or non-ECD.
CVA, cerebrovascular accident as the cause of donor death; HTN, 
preexisting history of hypertension; creatinine > 1.5, serum creatinine 






Outcomes Following ECD Kidney 
Transplantation
 
Kidney transplantation enhances quality of life and
improves patient survival in all patient groups (32,33).
However, the survival benefits seen in recipients of ECD
kidney transplants are inferior compared to recipients of
standard criteria donor kidneys. Using OPTN/SRTR data,
Danovitch et al. (23) reported that the annual death rate
for recipients of ECD kidneys was 100/1000 patient-years
at risk compared to 48/1000 patient-years at risks for
recipients of standard criteria kidneys. The adjusted patient
survival at 1 and 5 years for ECD kidneys was 90.6% and
69.9%, compared to 94.5% and 81.2% for non-ECD (or
standard criteria donor) kidneys, respectively (34).
Table 2 shows the survival rates for ECD and non-ECD
kidneys based on OPTN/SRTR, as reported by Metzger
et al. (34). Single-center studies are in general agreement
with registry data with respect to the inferior survival
seen with ECD kidneys, with a few exceptions (20). On
average, patient survival is 5% lower at 1 year and 8–
12% lower at 3–5 years for ECD kidney recipients (23,34).
Considered in another way, the projected added-life years
following a standard criteria donor kidney is 10 years
versus 5.1 years for ECD kidneys (33,35). Other recipient
characteristics such as age and race are associated with
more or less likelihood of survival benefit following ECD
kidney transplantation.
The finding of improved longevity with ECD kidney
transplantation relative to waiting lists is not a very
realistic comparison, as recipients who turn down the
offer for an ECD kidney are typically highly placed on
the waiting list and thus are likely to receive a standard
criteria donor kidney shortly thereafter. The ideal com-
parison in which ECD kidney transplant is compared
with the integral of the short additional waiting time and
receipt of a standard criteria donor kidney has not yet
been published.
The indices of renal allograft performance, such as
delayed graft function, acute rejection, and allograft
survival, are also often inferior in ECD transplants. In a
comparison of 37 ECD kidneys versus 53 standard criteria
donor kidneys, Stratta et al. (19) found no difference
between ECD and standard criteria donor kidney trans-
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estimated creatinine clearance was significantly lower in





(19). In a retrospective analysis of 582 DD transplants,
Keitel et al. (20) found no difference between ECD and





 = 203) and graft survival at 1 and 5 years





Notwithstanding these reports, large studies and ana-
lysis from transplant registries show significantly inferior
graft survival results for ECD kidneys when compared to
standard criteria donor kidneys (Table 2). On average,
the adjusted graft survival in ECD kidneys is 8% lower at
1 year and 15–20% lower at 3–5 years after transplantation
compared to standard criteria donor kidneys (23,34,36).
 
Impact of Recipient Characteristics on ECD 
Kidney Transplantation
 
The survival benefits of kidney transplantation are
strongly modified by recipient-based factors. Although
the overall survival in recipients of ECD kidneys is sig-
nificantly better than wait-listed dialysis patients, some
patient groups have been shown to receive no improve-
ment in patient survival following an ECD kidney trans-
plant (31). In patients with a waiting time of less than
1350 days, an ECD kidney resulted in no survival benefit
for patients older than 40 years, African Americans, or
Asians (31). Therefore nephrologists should be mindful
of recommending an ECD kidney to their patients who
meet these demographic criteria if the average waiting
time is less than 1350 days in their donation service area.
Apart from waiting time, recipient age, race, and cause
of end-stage renal disease (ESRD) may also modify the
magnitude of the clinical benefits from an ECD donor
transplant. Ojo et al. (37) reported a projected increase in
life span of 7.3 years in recipients of marginal donor
kidney transplants for patients age 55–64 years at the time
of kidney transplantation, whereas the corresponding
additional life span was decreased to 3.8 years in recipients
who were 65 years or older. Metzger et al. (34) found a
5-year patient survival of 69.0%, 71.7%, and 80.3% in
white, African American, and Asian ECD recipients,
respectively. The impact of these demographic char-
acteristics on patient survival after receiving a standard
criteria donor kidney transplant is not as large.
 
Trends Since Implementation of OPTN 
Allocation Policy 3.5.1 (ECD Kidneys)
 
One of the goals of the revised allocation policy for
ECD kidneys was to expedite the placement of these
TABLE 2. Patient and renal allograft survival in ECD and standard criteria donor kidneys from 3 months to 5 years posttransplant (34)
 
Survival time
Patient survival Allograft survival
Expanded criteria donor (%) Standard criteria donor (%) Expanded criteria donor (%) Standard criteria donor (%)
3 months 96.0 97.5 90.4 94.0
1 year 90.6 94.5 81.7 89.3
3 years 78.5 89.9 65.1 80.4




kidneys so that organ discard rates would be reduced. It
was anticipated that informed patient choice would
enhance the rate of procurement and expeditious disposi-
tion of the “kidneys that nobody wanted.” In 2003, the
number of ECD kidneys recovered increased by 18%,
compared to a 1% increase for standard criteria donor
kidneys (37). This increase accounted for most of the
7.7% increase in DD transplants performed in the United
States compared to the previous year (31). The mean
number of kidneys transplanted from ECD donors was
1.24, compared to 1.78 for non-ECD kidneys in donors
less than 60 years of age.
Expeditious placement of ECD kidneys seems to have
been realized even though the change in policy is rela-
tively new. The number of ECD kidneys transplanted
with a cold ischemia time of less than 12 hours increased
from 10% in 2001 to 17% in 2003 (23). By mid-2003,
almost half (43%) of all waiting list registrants indicated
a willingness to accept an ECD kidney. Since the alloca-
tion of an ECD kidney does not include points for human
leukocyte antigen (HLA) mismatch, except zero antigen
mismatch, the majority (52%) of ECD transplants were
highly mismatched (five to six HLA mismatches), which
represents a 40% increase in high grade HLA mismatched




Optimal utilization of ECD has not been fully realized.
Only a small group of recipients have been shown to be less
likely to benefit from receiving an ECD kidney transplant.
Judging the survival benefits of ECD kidney transplanta-
tion against maintenance dialysis therapy is not the ideal
comparison. Thus the decision as to which candidates are
most suitable for ECD kidney transplantation and whether
there are additional groups of patients for whom an ECD
kidney constitutes a prohibitive risk currently rely on an
incomplete ascertainment of benefits. In particular, there
are no published studies in which the survival benefits of
ECD transplants have been evaluated against the outcomes
in patients who declined ECD transplant and subsequently
received a non-ECD transplant. Resolving these types of
issues requires additional time and experience with the
new allocation policy and the development of appropriate
statistical analytic techniques.
Second, the current definition of an ECD kidney, while
simple to utilize, omits important donor-based prognostic
indicators. Histomorphologic kidney data, donor-recipient
weight ratio, and donor age less than 10 years were not
included in the current definition. It is therefore highly likely
that the current definition of ECD kidneys and allocation
policy will continue to undergo modifications as additional
data become available on more donor-related factors and
the impact of their interactions with recipient character-




Expanded criteria donor kidney transplantation has
introduced a new dimension to the process and outcomes
of kidney transplantation. By definition, recipients
transplanted with an ECD kidney have inferior graft and
patient survival results. Five-year graft and patient
survival are 15–20% and 8–13% lower, respectively, for
ECD kidneys. ECD kidneys account for 15–20% of DD
kidneys currently transplanted in the United States. Most
of the growth in DD transplantation now comes from
these ECD kidneys.
To date, only patients less than 40 years of age, African
American, or Asian listed in organ procurement organ-
ization (OPOs) with median waiting times of less than
1350 days are known not to be well served by receiving
ECD kidney transplants, as they stand to derive no clinical
benefits in terms of patient and graft survival. The new
allocation policy has lessened the overall frequency of
discarding kidneys and shortened the cold ischemia time
for ECD kidney transplantation. Evolutionary changes
in the current policy will be necessary as more is learned
about additional donor factors and recipient characteris-
tics that impact the outcome of ECD kidney transplan-
tation. Practicing nephrologists need to be more familiar
with the definition of ECD kidneys, the associated trans-
plant results, and the basic operations of the allocation
policy so that they can effectively counsel their patients
on whether to exercise the option for an ECD kidney (at
the time of registration for the waiting list) and assist
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We invite you to take part in a program to better use kidneys recovered from donors with conditions that make it more
difficult to efficiently place them for transplantation. Please take your time to make your decision. Discuss it with your
family and friends and feel free to ask us questions also. This program will not be recommended for all of our patients.
It is important that you read this document and understand several general principles that apply to all who take part in
our expanded criteria donor program.
This program has been developed by the Organ Procurement and Transplantation Network, the organization that man-
ages the national patient waiting list.
This program does not replace the waiting list already in place; it simply offers a means for some patients to receive a
transplant more quickly.
Taking part in this program is entirely voluntary.
Those participating in the program will still be participating in the regular waiting list program for the kidneys distrib-
uted through that listing.
You may withdraw from the program at any time without incurring any penalties or loss of waiting time points.
You are urged to ask any questions you have about this program of the staff members who explain it to you.
 
Why is this program being offered?
 
There is a serious shortage of cadaver kidneys (kidneys recovered from someone who died) while, at the same time,
transplantation is beneficial to an increasing number of patients with kidney failure. The waiting list increases by sev-
eral thousand each year and more than 4000 patients will die waiting for a kidney transplant this year. The waiting time
for a cadaver kidney is more than 4 years in most parts of the country. Many patients are waiting longer because their
transplant markers, which determine a kidney match, may not be very common and keep them from having enough
points to get a kidney offer.
One way to increase the number of cadaver kidneys is to use “expanded criteria” donors; these are donors who are




are transplanted. Many of these kidneys are already being transplanted, but a large number are discarded when the time
to get them transplanted is too long, resulting in too much damage. This new program will allow transplant centers to
use them locally without having to go entirely through the national system. We believe this will help those kidneys to
perform better and provide adequate function for the recipients to stop dialysis. A study done by the national kidney
program showed that patients receiving these kidneys add about 5 extra years to their life compared to not receiving a
transplant and remaining on dialysis.
You are being told about this program because you have kidney failure, you do not have a potential living kidney donor,
and, given your age and overall condition, you might receive significant benefit from an expanded criteria donor kidney.
 
What is involved in the program?
 
To take part in the program, you will be asked to sign this informed consent document. Kidneys from expanded criteria
donors will be offered only to patients who have agreed in advance to be considered for them. They will be offered first
to anyone on this list who is a perfect match. If there is no perfect match, then they will be offered to the compatible
patient waiting the longest on the list. The kidneys from donors who meet the following criteria will be placed by this
program. All donors 60 or older are considered expanded criteria donors and all donors between the ages of 50 and 59
who have two or more of the following: (1) the donor died from a stroke or cerebrovascular accident; (2) the donor had
a medical history of hypertension (high blood pressure); and/or (3) the donor’s most recent creatinine was 1.5 mg/dl
or greater (creatinine is a measure of how well the kidney works; normal values typically range from 0.6 to 1.2 mg/dl).
You will have all the medical tests and procedures that are part of the regular recipient medical examination if you do
or do not enroll in this program. You may require more frequent biopsies of the transplanted kidney to assess for kidney
function and potential rejection episodes after the transplant. You may require dialysis for a short period of time after
the transplant. Long-term kidney function may be less than that from a nonexpanded criteria donor kidney.
 
Are there any benefits to taking part in this program?
 
The main benefit would be to shorten the time you wait for a kidney transplant. Recent analysis of transplant data
showed that the longer you wait on dialysis for a transplant, the poorer the transplant outcome.
 
What other options are there?
 
Remember, you will still be listed on the regular waiting list for a nonexpanded donor kidney. You may also decline to
enroll in this program. Your other option would be a living donor transplant from a family member, a friend, or even a
willing stranger.
 
What are the costs?
 
You or your insurance company will be charged for the continuing medical care and/or hospitalization that are part of
the kidney transplant procedure. There are no additional or special costs that are part of the expanded criteria kidney
donor program.
 
What are my rights as a participant?
 
Taking part in this program is voluntary. You may choose not to take part in or leave the program at any time. If so,
your regular care will not be affected and you will not lose any of the benefits you would normally receive. We will try
to keep you informed of any new developments pertaining to this program.
 
Who do I call if I have any questions or problems?
 





As a representative of this program, I have explained the purpose, the procedures, the benefits, and the risks that are
involved in this program. Any questions that have been raised have been answered to the individual’s satisfaction.
__________________________________ ________
Signature of person obtaining the consent Date
I, the undersigned, have been informed about this program’s purpose, procedures, possible benefits and risks, and I
have received a copy of this consent document. I have been given the opportunity to ask questions and I have been told
I can ask questions in the future. I voluntarily agree ___________________ or do not agree ___________________
(initial appropriately) to participate in this program. I am free to withdraw from the program at any time without need
to justify my decision. A withdrawal will not in any way affect my future treatment or medical management.
__________________________________ ________
Signature of person obtaining the consent Date
